[1][2] Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes.

The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.

In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.

[3] In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.

[4] In January 2023, Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed thus causing the share price to plunge.